Yükleniyor... / Loading...
This study investigates inflammation and accompanying systemic conditions in people with moderate-to-severe plaque psoriasis, in the context of Etanercept treatment. It included patients over 18 with plaque psoriasis affecting at least 10% of the body surface. It is a non-phase study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Age ≥ 18years * Psoriasis affecting Body Surface Area (BSA) ≥ 10% after washout * No systemic anti psoriatic therapy ≤ 30days * Plaque type Psoriasis Exclusion Criteria: * Overt diabetes (\> 135 mg/dL fasting blood glucose on two (2) separate occasions * Hypertension as defined as a systolic BP \> 140 \&/or a diastolic pressure \> 90. -Cannot be on more then one (1) antihypertensive medication. * Currently have any known malignancy or have a history of malignancy in the 5 past years excluding basal cell carcinoma. * S/P Cardiovascular event such as Myocardial infarction, any open heart surgery, stroke or other vascular occlusive event. * Known allergy to etanercept * HIV positive * HBV positive * HbA1C \>7 * Current use of hypoglycemic medication * Current use of any anticoagulants * Current use of any anti-inflammatory medications (except inhaled steroids) * Females of childbearing age who are pregnant or breast-feeding or not using a contraceptive. * NYHA Class III and Class IV heart failure * Positive PPD * History, physical, or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the Principal Investigator, make the candidate ineligible for the study.